Prepare for up to a Dozen Humira Biosimilars
Up to 12 biosimilars for Humira (adalimumab) are slated to hit the market in 2023...starting with Amjevita in January.
This is a big deal. Humira is approved for several indications...rheumatoid arthritis, plaque psoriasis, Crohn’s, etc.
Plus it’s a top seller...annual revenue is over $20 billion.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote